To further investigate if the AR is the dominant mechanism of CRPC in other AR wt cell lines, we set out to generate an extensive panel (5–10 replicates per condition) of CRPC clones from 4 distinct AR wt PCa cell lines (VCaP, DuCaP, PC346C, and LAPC4) by growing them in androgen-depleted medium alone (ADT) or with ARTA BIC, FLU, or RD162, an antiandrogen with a similar molecular structure and antiandrogenic efficacy as enzalutamide and apalutamide (10). The gene discussed is AR; the disease is posterior cortical atrophy.